Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/12/2019
SIETES contiene 92850 citas

 
 
 1 a 10 de 10 
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Marciniak TA, Cherepanov V, Golukhova I, Hyun Kim M, Serebruany V. Drug discontinuation and follow-up rates in oral antithrombotic trials. JAMA Intern Med 2016;176:11 de enero. [Ref.ID 99961]
2. Cita con resumen
Anónimo. Antithrombotic drugs. Med Lett Drugs Ther 2014;56:103-8. [Ref.ID 98343]
3. Cita con resumen
Anónimo. Vorapaxar (Zontivity) for prevention of thrombotic cardiovascular events. Med Lett Drugs Ther 2014;56:85-6. [Ref.ID 98221]
4. Cita con resumen
Anónimo. Advertisement new blood thinner approved for select patients. DIA Daily 2014:9 de mayo. [Ref.ID 97577]
5. Cita con resumen
Anónimo. FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients . U.S. Food and Drug Administration 2014:8 de mayo. [Ref.ID 97512]
6.Enlace a cita original Cita con resumen
Anónimo. FDA Advisory panel votes in favor of approval for vorapaxar. U.S. Food and Drug Administration 2014:1. [Ref.ID 96991]
7. Cita con resumen
Krumholz HM. Cardiology top stories of 2012. Journal Watch 2012:26 de diciembre. [Ref.ID 93419]
8. Cita con resumen
Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KAA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJO, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA, for the TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404-13. [Ref.ID 92750]
9. Cita con resumen
Kosoglou T, Reyderman L, Kasserra C, Jennings LK, Young S, Xuan F, Pei J, Maxwell SE, Schiller J, Meehan AG, Cutler DL. No differences in the pharmacodynamics and pharmacokinetics on the thrombin receptor antagonist vorapaxar between healthy Japanse and Caucasian subjects. Eur J Clin Pharmacol 2012;68:291-300. [Ref.ID 92435]
10.
Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LHK, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW, for the TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:20-33. [Ref.ID 92104]
Seleccionar todas
 
 1 a 10 de 10